Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CEO James F. Oliviero III Sells 10,331 Shares of Stock

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CEO James F. Oliviero III sold 10,331 shares of the firm’s stock in a transaction on Monday, February 10th. The shares were sold at an average price of $3.15, for a total transaction of $32,542.65. Following the transaction, the chief executive officer now directly owns 3,775,019 shares of the company’s stock, valued at $11,891,309.85. The trade was a 0.27 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Checkpoint Therapeutics Trading Up 7.0 %

Shares of CKPT opened at $3.35 on Thursday. The firm’s fifty day simple moving average is $3.38 and its two-hundred day simple moving average is $3.00. Checkpoint Therapeutics, Inc. has a 12 month low of $1.38 and a 12 month high of $4.50. The stock has a market capitalization of $163.58 million, a P/E ratio of -1.82 and a beta of 1.36.

Checkpoint Therapeutics (NASDAQ:CKPT) last announced its earnings results on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.08). As a group, research analysts predict that Checkpoint Therapeutics, Inc. will post -0.94 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

CKPT has been the subject of several analyst reports. D. Boral Capital initiated coverage on Checkpoint Therapeutics in a research report on Monday, January 13th. They set a “buy” rating and a $9.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Checkpoint Therapeutics in a research note on Monday, December 16th. Finally, Lake Street Capital upped their target price on Checkpoint Therapeutics from $4.00 to $7.00 and gave the company a “buy” rating in a report on Monday, December 16th.

Hedge Funds Weigh In On Checkpoint Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Virtu Financial LLC bought a new stake in shares of Checkpoint Therapeutics in the 3rd quarter valued at $30,000. SBI Securities Co. Ltd. acquired a new stake in Checkpoint Therapeutics in the fourth quarter worth $32,000. PUREfi Wealth LLC bought a new stake in Checkpoint Therapeutics in the fourth quarter valued at $32,000. Bartlett & CO. Wealth Management LLC raised its holdings in shares of Checkpoint Therapeutics by 375.0% during the fourth quarter. Bartlett & CO. Wealth Management LLC now owns 19,000 shares of the company’s stock valued at $61,000 after purchasing an additional 15,000 shares during the period. Finally, Charles Schwab Investment Management Inc. bought a new position in shares of Checkpoint Therapeutics during the 4th quarter worth about $64,000. 22.00% of the stock is owned by institutional investors and hedge funds.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.